Lynx Capital 德石资本

Lynx Capital is a healthcare and life science -focused fund, investing in innovative companies in western countries in both therapeutics and medical technology areas, with a potential to collaborate with Chinese companies to explore the China market. With the extensive expertise and experience in both China and the States, and deep understanding of healthcare and business, Lynx Capital believes that it is well positioned to help with such collaboration.

BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 28, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. Shanghai-based Lynx Financial served as Aurealis' exclusive financial advisor in this transaction.

VIENNA, Austria, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

ESPOO, Finland, April 08, 2021 – Mobidiag to Be Acquired by Hologic, Innovator in Women’s Health Diagnostic Testing, for Approximately €668 Million

NEW YORK and CUPERTINO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) – Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2019-- Exicure, Inc., (NASDAQ:XCUR) and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

SAN JOSE, Calif., Sept. 30, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology

EDINBURGH, Scotland, Sept. 4, 2019 /PRNewswire/ --CALCIVIS Completes £4.5 Million Fund Raising Ahead of Anticipated PMA Approval of the CALCIVIS® Imaging System in the US

FINLAND Espoo/CHINA, Zhengzhou, June 3 2019 – Mobidiag announces launch of Automobi Molecular Diagnostics

BOTHELL, Wash., May 28, 2019 /PRNewswire/ -- Novuson Surgical, a Bothell, WA based medical device company, has secured funding from HOYA Corporation to finalize development for the UltraStat 3mm Vessel Sealer / Divider using Direct Therapeutic Ultrasound (DTU).